The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

ProFound Therapeutics will use its proteomic technology and Quotient Therapeutics its genomics platform to uncover respiratory and liver disease treatments.

"The CIRM grant will enable ReviR Therapeutics to further develop their preclinical candidate through rigorous preclinical studies and into clinical trials, with an initial goal to ensure that the ...

The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanO₂ as a radiosensitizer.

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The Shanghai-based firm will evaluate the safety of the therapy and its efficacy in reducing urinary oxalate levels and improving renal outcomes.